Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0...
FDA Drug Recall #D-0665-2024 — Class II — September 16, 2024
Recall Summary
| Recall Number | D-0665-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 16, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | AbbVie Inc. |
| Location | North Chicago, IL |
| Product Type | Drugs |
| Quantity | 763,426 tubes |
Product Description
Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230312042
Reason for Recall
Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.
Distribution Pattern
Nationwide in the USA, Foreign Consignees (Austrailia, Canada, Great Britain)
Lot / Code Information
Lot: 387489, Exp. Oct 24; 387490, Exp. Jun 25; 390422, Exp. Nov 24; 390424, Exp. Oct 24; 391692, Exp. Jun 25; 391893, Exp. Nov 25; 394822, Exp. Feb 26; 395991, Exp. Mar 26; 397905, 397973, 397974, Exp May 26; 399019, 399254, Exp. Jun 26; 399922, Exp. Jul 26; 408738, Exp. Mar 27; T3911, Exp. Sep 24; T4015, T4031, T4032, T4033, T4108, Exp. Oct 24.
Other Recalls from AbbVie Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0551-2026 | Class III | PRED MILD, prednisolone acetate ophthalmic susp... | May 18, 2026 |
| D-0664-2024 | Class II | Refresh P.M., (Mineral Oil 42.5%, White Petrola... | Sep 16, 2024 |
| D-0088-2024 | Class III | Synthroid, Levothyroxine Sodium Tablets, USP 12... | Oct 17, 2023 |
| D-0412-2018 | Class III | Ultane (sevoflurane), 250 mL, Inhalation Anesth... | Jan 22, 2018 |
| D-0034-2018 | Class III | AndroGel (testosterone gel) 1.62%, 40.5mg in 2.... | Sep 8, 2017 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.